Dietary potassium citrate does not harm the pcy mouse: A brief communication

Experimental Biology and Medicine

Volumn 230, Issue 1, 2005, Pages 57-60

  Tanner, Judith A ^a   Tanner, George A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autosomal dominant polycystic kidney disease; Citrate; Cystic kidney disease; Mouse kidney; Nephronophthisis

Indexed keywords

CITRATE POTASSIUM;

ALKALINIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONTROLLED STUDY; DIET; DISEASE COURSE; KIDNEY CYST; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MALE; MOUSE; MOUSE STRAIN; NEPHRONOPHTHISIS; NONHUMAN; SURVIVAL;

ANIMALIA;

EID: 11144322215     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000107     Document Type: Article

References (19)

1. Grantham JJ, Cowley BD Jr, Torres VE. Progression of autosomal dominant polycystic kidney disease to renal failure. In: Seldin DW, Giebisch G, Eds. The Kidney. Physiology and pathophysiology (3rd ed.). Philadelphia: Lippincott Williams & Wilkins, pp2513-2536, 2000.
2. Qian Q, Harris PC, Torres VE. Treatment prospects for autosomal-dominant polycystic kidney disease. Kidney Int 59:2005-2022, 2001.
3. Tanner GA. Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9:1242-1248, 1998.
4. Tanner GA, Tanner JA. Citrate therapy for polycystic kidney disease in rats. Kidney Int 58:1859-1869, 2000.
5. Tanner GA, Tanner JA. Dietary citrate treatment of polycystic kidney disease in rats. Nephron Physiol 93:14-20, 2003.
6. Tanner GA, Vijayalakshmi K, Tanner JA. Effects of potassium citrate/citric acid intake in a mouse model of polycystic kidney disease. Nephron 84:270-273, 2000.
7. Takahashi H, Calvet JP, Dittemore-Hoover D, Yoshida K, Grantham JJ, Gallone VH. A hereditary model of slowly progressive polycyslic kidney disease in lhe mouse. J Am Soc Nephrol 1:980-989, 1991.
8. Nagao S, Hibino T, Koyama Y, Marunouchi T, Konishi H, Takahashi H. Strain differences in expression of the adult-type polycystic kidney disease gene, pcy, in the mouse. Exp Anim 40:45-53, 1991.
9. Olbrich H, Fliegauf M, Hoefele J, Kispert A, Otto E, Volz A, Wolf MT, Sasmaz G, Trauer U, Reinhardl R, Sudbrak R, Antignac C, Gretz N, Walz G, Schermer B, Benzing T, Hildebrandl F, Omran H. Mutations in a novel gene, NPHP3, cause nephronophlhisis, tapeto-retinal degeneralion and hepatic fibrosis. Nat Genet 34:455-459, 2003.
10. Chaney AL, Marbach EP. Modified reagents for determination of urea and ammonia. Clin Chem 8:130-132, 1962.
11. Glantz SA. Primer of Biostatistics (5th ed.). New York: McGraw Hill, pp387-415, 2003.
12. May RC, Kelly RA, Mitch WE. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis. J Clin Invest 79:1099-1103, 1987.
13. Kamura K, Torres VE, Ishibashi M, Sasaki A, Joh K, Harris PC, Yamada K. Renal functional abnormalities in the PCK rat, a model of human ARPKD. J Am Soc Nephrol 13:115A, 2002.
14. Takashi Y, Fumio I, Yukinari O, Shigeru H, Chika K, Hiroshi T. What are the effects of citrate on experimental polycystic kidney disease? Eur Urol Suppl 1:142, 2002.
15. Omran H, Fernandez C, Jung M, Häffner K, Fargier B, Villaquiran A, Waldherr R, Gretz N, Brandis M, Rüschendorf F, Reis A, Hildebrandt F. Identification of a new gene locus for adolescent nephronophthisis, on chromosome 3q22 in a large Venezuelan pedigree. Am J Hum Genet 66:118-127, 2000.
16. Omran H, Häffner K, Burth S, Fernandez C, Fargier B, Villaquiran A, Nothwang H-G, Schnittger S, Lehrach H, Woo D, Brandis M, Sudbrak R, Hildebrandt F. Human adolescent nephronophthisis: gene locus synteny with polycystic kidney disease in pcy mice. J Am Soc Nephrol 12:107-113, 2001.
17. Torres VE, Cowley BD Jr, Branden MG, Yoshida I, Gattone VH. Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 9:171-180, 2001.
18. Gattone VH II, Wang X, Harris PC, Torres VE. Inhibilion of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Med 9:1323-1326, 2003.
19. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH II. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med 10:363-364, 2004.